drugset / Trial / NCT03443843

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

NCT03443843

Phase 4 Completed 82 enrolled Bayer
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.

Timeline

Start
2018-02-21
Primary completion
2018-05-11
Completion
2018-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 50 ug Intranasal
Subject Loratadine Small molecule 5 mg Oral
Subject Pseudoephedrine Small molecule 120 mg Oral

Indications